ǰÑÔ
°×Ѫ²¡(leukemia)ÊÇÔìѪ×éÖ¯µÄ¶ñÐÔÔöÖ³ÐÔ¼²²¡£¬ÆäÌØµãÊǹÇËè¼°ÆäËûÔìѪ×éÖ¯Öдó×ÚÎÞºËϸ°ûÎÞÏÞÖÆÔöÉú£¬½øÈëÍâÖÜѪҺ£¬ÁÙ´²ÌåÏÖÒÔ¹ÇË衢Ƣ¡¢¸ÎµÈÔìѪÆ÷¹ÙÖеİ×Ѫ²¡Ï¸°û¶ñÐÔÔöÉúÓëÖ״󣬲¢½þÈóµ½È«Éí¸÷×éÖ¯ÔàÆ÷ÖУ¬°éÓвî±ðˮƽµÄѪÐé¡¢³öѪ¡¢Ñ¬È¾·¢ÈÈÒÔ¼°¹Ç÷ÀÌÛÍ´¡£°×Ѫ²¡µÄ·¢²¡ÂʺÍéæÃüÂÊÖðÄêÔöÌí£¬¾Ó35ËêÒÔÏÂÇàÉÙÄê¶ñÐÔÖ×ÁöµÄÊ×λ¡£Òò´Ë£¬ÖƱ¸ÏìÓ¦µÄ¶¯ÎïÄ£×Ó¶ÔÆäÑо¿¾ßÓÐÖ÷ÒªµÄÒâÒå¡£¾ø´ó´ó¶¼ÈËÀà°×Ѫ²¡¿ÉÒÔÓû¯Ñ§£¨ÈçÉÕ»¯¼Á£©¡¢ÎïÀí£¨ÈçµçÀë·øÉ䣩¡¢ÉúÎÈ練ת¼²¡¶¾£©ÒÔ¼°×ª»ùÒòÒªÁ죬ÔÚ²î±ð¶¯ÎСÊó¡¢ëàÊó¡¢´óÊó¡¢Ã¨¡¢Å£¡¢³¤±ÛÔ³µÈ£©ÖÐÓÕ·¢°×Ѫ²¡£¬½¨É趯ÎïÄ£×Ó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
bcr/ablת»ùÒòСÊóÄ£×Ó£ºÍ¨¹ý¿Ë¡ÆÊÎöСÊóTec»ùÒòµÄÆô¶¯×ÓÐòÁк͹¦Ð§£¬·¢Ã÷ÓÉTecÆô¶¯×Óµ÷¿ØµÄ»ùÒò½öÌØÒìÐԵرí´ïÔÚÔìѪ¸Éϸ °ûµÄϸ°ûÖÊÖС£½ÓÄÉСÊóµÄTec»ùÒòµÄÆô¶¯×ÓÐòÁУ¬ÖƱ¸×ª»ùÒòÔØÌ壬Я´ø°×Ѫ²¡Ïà¹Ø»ùÒòbcr/abl£¬ÖƱ¸×ª»ùÒò¶¯Îת»ùÒòСÊóÊ×ÏÈ·ºÆðÁ£Ï¸°ûÒì³£ÔöÉú¡¢¸ßѪС°åѪ֢£¬¾Ò»×¼Ê±¼äºó±¬·¢¹ÇËèÔöÖ³×ÛºÏÕ÷£¬ºÍÈËCML¼«ÎªÏàËÆ¡£ÆäÖÐÓÐת»ùÒòÊóÔÚ³öÉúºó¼´ÌåÏÖΪ¼±ÐÔ°×Ѫ²¡£¬µ«ËüÃǵÄ×Ó´ú¾ÓÉÒ»¶ÎDZÔÚÆÚºóÌåÏÖ¹ÇËèÔöÉú×ÛºÏÕ÷¡£ÁíÍâÒ»ÖÖת»ùÒòСÊóÊǸ߱í´ïÒ»Á¬»î»¯µÄÍ»±äStat5£¬´ËÍ»±äµÄstat5Я´ø2¸öÍ»±äλµã£¬¿ÉÒÔºÍÄÚÔ´ÐÔstat5ÍŽᣬÐγɶþ¾ÛÌ壬һÁ¬»î»¯¡£ÕâÖÖСÊóÉú³¤·¢ÓýÀú³ÌÖб¬·¢°×Ѫ²¡¡£ÉÐÓÐÍ»±ä»ùÒòÇÃÈë(knock-in)Ä£×Ó¡£È磬SHP-2D61G¡¢SHP-2E76K»ùÒòÇÃÈëСÊ󣬾ù±¬·¢°×Ѫ²¡¡£
¡¾Ä£×ÓÌØµã¡¿£º
ʹÓòî±ðµÄÆô¶¯×ÓÒѽ¨ÉèÆð¼¸¸öÄÜÄ£ÄâÈËCMLµÄת»ùÒòСÊóƷϵ¡£Ó뷴ת¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÏà±È£¬×ª»ùÒòСÊóÄ£×ÓÓÐÒÔϼ¸¸öÓŵ㣺¢Ùbcr/abl»ùÒò×÷Ϊת»ùÒòСÊóµÄÒ»²¿·ÖÔÚÌåÄÚ±í´ï£¬¸üÄÜ׼ȷµØÄ£ÄâÈËCML£»¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÔÚϸ°û×÷Óý¡¢ÒÆÖ²Àú³ÌÊÜÐí¶àϸ°ûÒò×ÓµÄÓ°Ï죬ÕâЩϸ°ûÒò×Ӻʹ¦Öóͷ£ÊÜÌåÊóµÄÆäËûÒòËØ¶¼¶Ô¼²²¡µÄ±íÐÍÓнϴóµÄÓ°Ïì¡£¢Úbcr/ablת»ùÒòÊó¿ÉÒÔ´«´ú£¬¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓÐëÖØÐ½¨Éè¡£¢Ûת»ùÒòCMLÄ£×ÓÓÐÒ»¶¨µÄDZÔÚÆÚ£¬ÕâÓëÈ˵ÄCML¼«ÎªÏàËÆ£»¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²·¨½¨ÉèµÄCMLÄ£×ÓDZÔÚÆÚ¶Ì£¬µ¹ÔËÓÚÈËCML·¢²¡Ç°»úÖÆµÄÑо¿¡£¢Üת»ùÒòÊóµÄCMLÓÐÀàËÆÓÚÈËCMLµÄµ¥¿Ë¡ÐÔ£¬¶ø·´×ªÂ¼²¡¶¾×ªÈ¾²¢ÒÆÖ²ÊóµÄCMLÊǶà¿Ë¡µÄ¡£×ª»ùÒòCMLÒ²±£´æÒ»Ð©Èõµã£º¢Ùת»ùÒò¶¯ÎïµÄÿһ¸öϸ°û¶¼ÓÐbcr/abl»ùÒòµÄ±í´ï£¬¶øÈ˵ÄCMLÖ»ÔÚÔìѪ¸Éϸ°ûºÍ×æÏ¸°ûÖбí´ï£¬Õâ»òÐí»áÓ°ÏìCMLµÄ²¡ÀíÌØÕ÷ºÍÖÎÁÆÇéÐΣ»¢ÚSHP-2061GСÊóÕý³£Éú³¤·¢ÓýÀú³ÌÖнö±¬·¢ËèϵÔöÖ³²¡£¬µ«·øÕպ󱬷¢°×Ѫ²¡¼°ÆäËûÖ×Áö£»¢ÛSHP-2E76KÊÇÌõ¼þÐÔÇÃÈëСÊó£¬Åß̥СÊóÈôÊÇѪҺϵͳ±í´ïSHP-2E76KÍ»±ä»áµ¼ÖÂСÊóÅßÌ¥ÖÂËÀ£¬ÒÔÊǽöÔÚСÊó³öÉúºó£¬ÓÃPoly I:CÓÕµ¼ÑªÒºÏµÍ³Cre±í´ï£¬µ¼ÖÂСÊóÔìѪ¸Éϸ°û»òÕß×æÏ¸°û±í´ïSHP-2E76KÍ»±äÂѰף¬Ð¡Ê󱬷¢°×Ѫ²¡¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ÓÉÓÚbcr/ablת»ùÒòСÊóÄ£×Ó±£´æÒÅ´«»¹²»·óÎȹ̡¢Ä£ÄâCML»¹²»·ó׼ȷµÈÈõµã£¬Òò´Ë»¹ÐèҪѰÕÒ¸üºÏÊÊµÄÆô¶¯×Ó£¬Ì½Ë÷¸ü±ãµ±µÄת»ùÒò¶¯ÎïÒªÁ죬ʵÑé¸ü½üËÆµÄ¶¯ÎïÆ·ÖÖ¡£ÏÖÔÚÖ÷ÒªÓÃÓÚÒÔÏÂ3·½ÃæµÄÑо¿£ºÖ¤ÊµCMLÊÇ·ñÔìѪ¸Éϸ°ûÔ´ÐÔ£¬Ñо¿bcr/abl»ùÒòÓëÆäËûÏà¹Ø»ùÒò¶Ô°×Ѫ²¡ÅäºÏÓ°Ï죬ÖÎÁÆÒ©ÎïµÄɸѡ¡£SHP-2061G¼°SHP-2E76KÇÃÈëСÊóÊǺܺõİ×Ѫ²¡¶¯ÎïÄ£×Ó£¬µ«ÐèÒªÉÌÆ·»¯¡£
²Î¿¼ÎÄÏ×£º
1.µËÑï¼Î£¬ÐìÒèÖ¥£¬Â¦ÊÀ·æ£®¼±ÐÔËèÐÔ°×Ѫ²¡SCIDСÊóÄ£×ӵĽ¨Éè¼°Åжϣ®ÏÖ´úÉúÎïҽѧϣÍû£¬2008,8(1): 53-55
2.ÖìÓñ·å£¬ÍõÔªÕ¼£¬ÃÏ·²Ò壮BCR/ABLת»ùÒò¶¯ÎïÄ£×ÓÑо¿Ï£Íû¼°Ó¦Óã®ÖйúʵÑéѪҺѧÔÓÖ¾£¬2011,19 (6):1532-1535
3.Áõ࣬¼¾Ã÷´º£¬Àîºñ´ï. ÈËÂýÐÔÁ£Ï¸°û°×Ѫ²¡¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾£¬2005,15 (1):55-58
4.ÀîÀöϼ£¬ÌÀÓÀÃñ£¬¹ËΰÖÒ£¬µÈ£®¼±ÐÔBÁܰÍϸ°û°×Ѫ²¡¶¯ÎïÄ£×ӵĽ¨Éè. Õã½´óѧѧ±¨£ºÒ½Ñ§°æ£¬2008,37(5): 511-514
5.ÑîÏþöï. Ö£¾þËÉ£¬ÕÅУ¬µÈ£®GITR¿¹Ìå¶ÔL615°×Ѫ²¡ÒÖÖÆ×÷ÓõÄʵÑéÑо¿. µÚÈý¾üÒ½´óѧѧ±¨£¬2006,28 (18):1837-1841
6.ÖÜÏþÑ࣬×ÞÁÕ£®°×Ѫ²¡Ð¡ÊóÄ£×ӵĽ¨ÉèÓëÓ¦ÓÃÏÖ×´£®·Ö×ÓÕï¶ÏÓëÖÎÁÆÔÓÖ¾£¬2011,3 (3):212-216
7.Ohsugi T, Yamaguchi K, Kumasaka T, et a]_ Rapid tumor death model for evalualion of new therapeutic agents for adult T-cell leukemia. Lab Invest,2004, 84 (2): 263-266
8.Ramshaw HS, Bardy PG, Lee MA, el al. Chronic myelomoaocylic leukemia requires granulocyte macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol,2002,30(10):1124-1131
9.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem, 2009, 284 (2):913-920
10.Xu D,Wang S,Yu WM,et al. A germline gain-offunction mutation in Ptpn 11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hemalopoielic stem cells. Blood, 2010, 116(18):3611-3621